VOR

Vor Biopharma's stock experienced several notable events in the past six months. The company reported inducement grants under Nasdaq Listing Rule 5635(c)(4) on multiple occasions. On March 30, 2026, Vor Biopharma reported its Fourth Quarter and Full Year 2025 Financial Results and provided a corporate update, including dosing the first patient in the global Phase 3 UPSTREAM SjD trial and a $75.0 million private placement with TCGX. Director RA Capital Management, LLC executed significant sales of Vor Biopharma stock in April 2026. Multiple analysts updated their views on VOR following clinical and financing developments, with some reducing price targets. As of May 7, 2026, the stock had decreased by 4.57% in the past month, but since the beginning of 2026, the stock had increased by 22.94%, and over the past 12 months, the stock gained 50.1%.